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Abstract: Due to the unique biodiversity and the physical-chemical properties of their environment,
marine microorganisms have evolved defense and signaling compounds that often have no equivalent
in terrestrial habitats. The aim of this study was to screen extracts of the dinoflagellate Amphidinium
carterae for possible bioactivities (i.e., anticancer, anti-inflammatory, anti-diabetes, antibacterial and
antifungal properties) and identify bioactive compounds. Anticancer activity was evaluated on human
lung adenocarcinoma (A549), human skin melanoma (A2058), human hepatocellular carcinoma
(HepG2), human breast adenocarcinoma (MCF7) and human pancreas carcinoma (MiaPaca-2) cell lines.
Antimicrobial activities were evaluated against Gram-positive bacteria (Staphylococcus aureus MRSA
and MSSA), Gram-negative bacteria (i.e., Escherichia coli and Klebsiella pneumoniae), Mycobacterium
tuberculosis and the fungus Aspergillus fumigatus. The results indicated moderate biological activities
against all the cancer cells lines and microorganisms tested. Bioassay-guided fractionation assisted by
HRMS analysis allowed the detection of one new and two known amphidinols that are potentially
responsible for the antifungal and cytotoxic activities observed. Further isolation, purification and
structural elucidation led to a new amphidinol, named amphidinol 22. The planar structure of the
new compound was determined by analysis of its HRMS and 1D and 2D NMR spectra. Its biological
activity was evaluated, and it displayed both anticancer and antifungal activities.
Keywords: marine microalgae; dinoflagellates; marine natural products (MNPs); bioactive
compounds; blue biotechnology; amphidinol; antifungal; anticancer
1. Introduction
Many microalgae, including dinoflagellates, are known to produce compounds with a wide range
of biological and biochemical properties [1]. The biodiversity of marine phytoplankton species leads
to a great metabolic variety that renders them a huge reservoir of new bioactive compounds with
multiple possible pharmaceutical applications [2] (e.g. cytotoxic, anticancer, antibiotic, antifungal,
immunosuppressant and neurotoxic activities [3–10]). Bioactive compounds of microalgal origin can
be sourced directly from primary metabolism (e.g. proteins, fatty acids, vitamins and pigments) or
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can be synthesized from secondary metabolism. Microalgae are in fact excellent sources/producers of
carotenoids, polysaccharides, vitamins, lipids as well as potent neurotoxins [11]. In the last decade,
an increasing number of studies have focused their attention on microalgal compounds for the treatment
of various human pathologies or for nutraceutical applications [12,13].
Amphidinium carterae is an athecate dinoflagellate, found in both temperate and tropical waters [14].
Pagliara and Caroppo [15] showed that when embryos of the sea urchin Paracentrotus lividus were
reared on a Mediterranean strain of A. carterae, there was a 60% embryo growth inhibition after exposure
to 3.75 mg/mL of A. carterae cell lysate and 100% inhibition with 7.5 mg/mL. They also observed an
LC50 value of 3.67 mg/mL after 24 h exposure of the brine shrimp Artemia salina to the A. carterae cell
lysate. Shah and co-workers found antioxidant activity at 1 mg/mL of methanolic extract of A. carterae,
80% nitric oxide (NO) production inhibition at 50 µg/mL in LPS-induced RAW 264.7 macrophages and
20% reduction in human promyelocytic leukemia (HL-60) cell viability at 50 µg/mL [16]. In addition,
it was also reported that an extract from another Amphidinium strain had antifungal properties and
was able to inhibit the growth of the fungus Candida albicans at 32 µg/mL [17].
Until now, various Amphidinium strains have displayed different biological activities and chemical
diversity [17–23]. Various compounds have been isolated from these strains, including the amphidinols
(AM), amphirionins, karatungiols and more than 45 cytotoxic macrolides, known as amphidinolides.
Most of the mentioned compounds present polyketidic skeletons, but it seems that not all of the
Amphidinium strains possess the enzymatic machinery responsible for polyketide synthesis [24,25].
The aim of this study was to screen A. carterae (clone FE102) for various bioactivities useful for the
treatment of human pathologies (i.e., anticancer, antibacterial and antifungal properties) and isolate
potential active metabolites. In the transcriptome of the same clone, we recently found the sequence
coding β-ketosynthase [26], an enzyme involved in polyketide synthesis, suggesting the production
of potential active secondary metabolites. Raw extracts from A. carterae were tested against various
bioactivity platforms including both human and bacterial cells. We evaluated the anti-bacterial activity
on Gram-positive bacteria (Staphylococcus aureus MRSA, Staphylococcus aureus MSSA), Gram-negative
bacteria (Escherichia coli and Klebsiella pneumoniae) and Mycobacterium tuberculosis. The antifungal activity
was assessed on Aspergillus fumigatus. Anticancer activity was also evaluated against a panel of five
different cancer cell lines (i.e., human lung carcinoma A549 ATCC® CCL-185™, human skin melanoma
A2058 ATCC® CRL-11147™, hepatocyte carcinoma HepG2 ATCC® HB-8065™, breast adenocarcinoma
MCF7 ATCC® HTB-22™ and pancreas carcinoma MiaPaca-2 ATCC® CRL-1420™). Bioassay-guided
fractionation followed by HRMS analyses yielded the new amphidinol 22. The amphidinols are a
family of bioactive polyketides with a well-known antifungal and hemolytic activity, as reported in the
literature [17,21,27,28]. Espiritu et al. have also reported that amphidinol 2 (AM2) displayed anticancer
properties [29]. Amphidinol 22 biological activity was evaluated and it showed both anticancer and
antifungal activity.
2. Experimental Section
2.1. Cell Culturing and Harvesting
A. carterae (CCMP1314) was grown in Keller medium [30] in ten-liter polycarbonate carboys (each
experiment was performed in triplicate) constantly bubbled with air filtered through 0.2 µm membrane
filters. Cultures were kept in a climate chamber at 20 ◦C on a 12:12 h light:dark cycle at 110 µmol
photons m−2 s−1. Initial cell concentrations were about 5000 cells/mL for each experiment and culture
growth rate was monitored, using the equation for net growth estimates [31]. For the isolation of the
pure compound, fifteen replicates of ten-liter cultures have been used. The biomass was harvested
during the stationary phase (in the same day and at the same time of the day for each replicate to
avoid possible interference by intrinsic circadian rhythms) by centrifugation for 10 min at 4 ◦C at
2300 rpm (Beckman Coulter Allegra® 6R centrifuge). Microalgal biomasses were kept at −80 ◦C until
chemical extraction.
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2.2. Chemical Extraction
Methanol was filled into the tubes to reach two times the volume of the biomass. The tubes
were vortexed to ensure that methanol completely soaked the material that was then placed into a
Kuhner ISF4-X Climo-Shaker for 3 h at 20 ◦C. The tubes were then centrifuged at 3000 rpm for 20 min,
and the supernatant was transferred to 40 mL EPA vials (dispolab) and evaporated under nitrogen
stream. Aliquots from the dried extracts were lyophilized and dissolved in DMSO for testing and
HPLC-UV-MS analysis. The extract yield of the A. carterae broth was 50 mg/L approximately.
2.3. Anticancer Assays
Colorimetric MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) assays were
carried out to assess the cell viability of the samples against a panel of five different cancer cell
lines (i.e., human lung carcinoma A549 ATCC® CCL-185™, human skin melanoma A2058 ATCC®
CRL-11147™, hepatocyte carcinoma HepG2 ATCC® HB-8065™, breast adenocarcinoma MCF7 ATCC®
HTB-22™ and pancreas carcinoma MiaPaca-2 ATCC® CRL-1420™). All cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA, USA). A549 cells were grown in Ham′s F12K
medium with 2 mM Glutamine, 10% Fetal Bovine Serum (FBS), 100 U/mL penicillin and 100 µg/mL
streptomycin. A2058 and HepG2 were grown in ATCC formulated Eagle’s M essential medium (MEM)
with 10% FBS, 2 mM l-glutamine, 1 mM sodium pyruvate and 100 µM MEM non-essential amino
acids. MCF-7 cells were grown in the previous medium supplemented with 0.01 mg/mL of bovine
insulin. MiaPaca-2 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10%
FBS, 100U/mL penicillin and 100 µg/mL streptomycin. The bioassays were performed as reported
by Audoin et al. [32]. The anticancer activity was assessed after 72 h of treatment with amphidinol
22 at the concentrations 0.098, 0.195, 0.391, 0.781, 1.563, 3.125, 6.250, 12.5, 25 and 50 µM. The raw algal
extract was tested at 175 µg/mL.
2.4. Antifungal Assays
The fungi C. albicans ATCC64124 and A. fumigatus ATCC46645 were used as test organisms to
assess antifungal activity as reported in Audoin et al. [32]. For C. albicans the growth inhibition was
calculated measuring the OD at 612 nm, while for A. fumigatus it was based on the fluorescence
development derived from the conversion of resazurin to resorufin (excitation 570 nm and emission
600 nm). The antifungal activity was assessed after 20–30 h of treatment with amphidinol 22 at the
concentrations 0.075, 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10, 20 and 40 µM. The raw algal extract was tested at
560 µg/mL.
2.5. Antibacterial Assays
A panel of five different bacteria (i.e., the Gram-negative bacteria E. coli ATCC25922 and K.
pneumoniae ATCC700603, and Gram-positive bacteria S. aureus MRSA MB5393 and MSSA ATCC29213)
were used as test organisms for the antibacterial MIC (minimum inhibitory concentration) assays that
were performed as reported in Audoin et al. [32]. The antibacterial activity was assessed after 20 h of
treatment with amphidinol 22 at the concentrations 0.075, 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10, 20 and 40 µM.
The raw algal extract was tested at 560 µg/mL. The antitubercular activity of the samples against M.
tuberculosis H37Ra was determined using the REMA method [33].
2.6. General Chemical Analysis Procedures
Samples were analyzed by HPLC-UV-HRMS on an Agilent 1200 RR coupled to a Bruker maXis
time-of-flight spectrometer with electrospray ionization, as reported by Martin et al. [34]. Mass spectra
were collected as full scans from 50 m/z to 2000 m/z. Data were analyzed using the platform available
at Fundación MEDINA [35] and compared with the data available in the Dictionary of Marine Natural
Products database [36] and PubChem [37]. NMR spectra were acquired using a Bruker Avance 500 MHz
Mar. Drugs 2019, 17, 385 4 of 13
spectrometer with a pulsed field gradient and referenced to signal solvent signals (CD3OD, at δH
3.31 and δC 49.0 ppm). The solvents used were HPLC grade.
2.7. Fractionation
The crude microalgal extract (5.67 g) was fractionated through reverse phase C18 (110 mm ×
40 mm column) flash chromatography to separate the extract into 80 different fractions using a gradient
of H2O (Solvent A) and CH3CN (Solvent B). The method went from 5% B to 100% B in 40 min and
it was maintained at 100% B for another 40 min. The flow rate was 18 mL/min and the wavelengths
selected were 210 and 260 nm, according to the data from HPLC-UV-MS. The fractions 19 and 20
(17.73 mg, eluted at 48% B) were pooled and further fractionated by semi-preparative reversed-phase
HPLC-DAD (column Zorbax SB-C8, 4.6 mm × 150 mm, 5 µm particle size) with a flow of 3.6 mL/min
and a H2O:CH3CN gradient (75:25 to 68:32 in 36 min) as eluent. Amphidinol 18 (identified by
HPLC-UV-MS) and amphidinol 22 were isolated. Amphidinol 22 was obtained as a pale yellow solid
(1.4 mg) and it was tested for anticancer, antifungal and antibacterial activity using 10-point serial
dilutions (1:1 dilutions), with initial concentrations of 50 µM in the case of the anticancer assays,
and 40 µM in the case of the antibacterial and antifungal assays.
2.8. Amphidinol 22
Pale yellow, amorphous solid; UV (MeOH) λmax 282, 270 and 260 nm; NMR data available
(CD3OD), see Table 1; HRESIMS m/z 1662.9705 [M + NH4]+ (calcd for C84H144O31N+, 1662.9717, ∆
−0.7 ppm); 1645.9515 [M + H]+ (calcd for C84H141O31+, 1645.9451, ∆ 3.9 ppm); 1627.9371 [M−H2O +
H]+ (calcd for C84H139O30+, 1627.9346, ∆ 1.5 ppm). 1H NMR (500 MHz), 13C NMR (125 MHz), HSQC,
COSY, HMBC, NOESY, LC-UV trace and UV and HRESIMS spectra of amphidinol 22, expansions of the
HRESIMS spectrum, and the tabulated 2D NMR data are available in the supplementary information
(Figures S1–S8 and Table S9, respectively).
2.9. Statistical Analysis
Statistical differences between treated and control cells for all the assays performed in this study
were determined by Student’s t-test using GraphPad Prim statistic software, V4.00 (GraphPad Software,
San Diego, California, USA). Data were considered significant when at least p was <0.05 (* for p < 0.05,
** for p < 0.01, and *** for p < 0.001).
3. Results and Discussion
3.1. Preliminary Bioactivity Screening of Raw Extract and HPLC-UV-MS Analysis
The isolation of new bioactive metabolites was performed following a bioassay-guided
fractionation approach supported by HRMS analysis. After extraction of the A. carterae biomass,
the crude extract was tested against a panel of different cancer cell lines, bacteria and fungi. For each
assay, three biological replicates were tested and two technical replicates per sample were performed.
Table 2 summarizes the outputs from the bioassays.
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Table 1. NMR data of amphidinol 22 (500 MHz) in CD3OD.
Carbon δ13C δ1H, mult, J (Hz) Carbon δ13C δ1H, mult, J (Hz)
1 14.09 0.91, t, 7.4 43 41.90 1.97, m; 1.51, m
2 23.58 1.42, m, 2H 44 71.79 3.85, m
3 35.83 2.06, m 45 36.68 1.67, m; 1.58, m
4 136.10 5.69, m 46 36.68 2.20, m; 2.11, m
5 131.23 6.05, dd, 15.2, 10.5 47 139.30 Null
6 132.41 6.22, dd, 15.7, 10.4 48 126.24 5.48, br d, 8.7
7 134.08 5.61, dd, 15.2, 8.6 49 67.97 4.56, dd, 8.9, 1.7
8 71.39 4.26, ddd, 6.6, 6.6, 6.6 50 72.50 3.68, dd, 9.5, 1.9
9 40.90 1.75, m, 2H 51 79.21 3.95, m
11 62.32 2.72, dd, 5.2, 2.1 53 67.48 3.97, m
12 71.91 3.41, m 54 30.41 1.76, m
13 35.35 1.62, m; 1.48, m 55 75.71 3.48, m
14 22.89 1.77, m; 1.44, m 56 74.63 3.60, m
15 32.90 1.89, m; 1.44, m 57 32.44 1.96, m; 1.55, m
16 81.54 3.07, m 58 27.89 2.41, m; 2.09, m
17 73.10 3.38, m 59 151.35 Null
18 76.77 3.39, m 60 76.77 4.18, d, 8.9
19 69.89 4.08, m 61 75.23 3.35, m
20 82.36 3.14, br d, 8.9 62 70.41 4.04, m
21 68.63 3.87, m 63 31.55 2.08, m; 1.55, m
22 35.14 2.05, m; 1.74, m 64 67.36 4.05, m
23 77.92 4.22, m 65 68.73 4.04, m
24 71.63 3.64, m 66 80.58 3.74, br d, 9.9
25 67.32 3.92, m 67 72.01 3.97, m
26 30.41 1.76, m 68 74.22 4.37, dd, 7.6, 2.9
27 74.63 3.54, m 69 129.15 5.63, dd, 16.5, 8.0
28 72.59 3.71, m 70 134.97 5.80, m
29 36.76 1.70, m; 1.38, m 71 33.59 2.19, m
30 33.59 1.97, m 72 33.65 2.21, m
31 79.41 3.12, dd, 7.6, 2.8 73 135.94 5.78, m
32 70.50 3.85, m 74 131.97 6.10, dd, 15.2, 10.4
33 46.06 2.29, m 75 134.75 6.21, dd, 15.7, 10.2
34 136.85 null 76 132.68 6.13, dd, 15.7, 10.2
35 129.54 5.72, br s 77 138.61 6.35, ddd, 16.9, 10.2, 10.2
36 144.65 null 78 116.68 5.15, dd, 17.0, 1.0; 5.01, dd, 10.2, 1.0
37 47.72 2.27, m; 2.21, m 79 17.25 0.97, d, 6.8
38 68.68 3.80, m 80 18.51 1.84, br s
39 42.50 1.63, m; 1.27 m 81 115.77 5.05, br s; 4.85, br s
40 31.15 2.12, m 82 13.91 0.90, d, 7.4
41 77.13 3.33, m 83 17.39 1.74, br s
42 72.68 3.64, m 84 113.21 5.07, br s; 4.98 br s
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Table 2. Percentage of growth inhibition of raw A. carterae extracts on cancer cells, bacteria and fungi.
Anticancer screening a
Cancer cell line A549 A2058 HepG2 MCF7 MiaPaca-2
% Growth Inhibition 100 100 100 100 100
Antibacterial screening b
Bacteria E. coli K. pneumoniae MRSA MSSA M. tuberculosis
% Growth Inhibition 37 19 95 88 83
Antifungal screening b
Fungus A. fumigatus
% Growth Inhibition 100
a Tested at a concentration of 175 µg/mL. b Tested at a concentration of 560 µg/mL. The values are the mean of three
biological replicates and two technical replicates.
The crude methanol extract from A. carterae seemed to possess unspecific bioactivity and a clear
toxicity profile, considering all the results from the cells and microorganisms tested. This was not
surprising, since marine dinoflagellates belonging to the genus Amphidinium are well-known producers
of different toxins [38], such as the amphidinolides [18].
Early HPLC-UV-MS analysis on the crude extracts revealed the presence of three possible
amphidinols that were singled out because of their characteristic UV pattern (showing maxima of
absorbance at 260, 270 and 280 nm due to a conjugated triene substructure), retention time and its m/z
values, which were close to some of the already known amphidinols [17,21]. The presence of these
compounds may explain the antifungal and anticancer activities observed within the crude extract.
A 10 mg aliquot from the crude extract was fractionated by semipreparative HPLC-DAD as
reported in the methods section. Seven fractions (F1 to F7) were collected, dried, dissolved in 100%
DMSO and tested against A. fumigatus and C. albicans (Figure 1).
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HPLC-UV-MS analysis of the fractions and dereplication of the molecular formulae obtained led
to the identification of F1 and F4 as amphidinol 19 (AM19, exact mass 1438.7894) and amphidinol 18
(AM18, exact mass 1358.8326), respectively (Figure 1). These two compounds were already discovered
and tested by Nuzzo et al. [17]. In particular, AM18 displayed antifungal activity against C. albicans at
9 µg/mL, but AM19 was not active. F2 was identified as an unknown compound related to amphidinols
with a relatively high experimental accurate mass of 1644.9437. The largest amphidinols described
so far were amphidinol 20 (AM20) and amphidinol 21 (AM21) [21], and their masses did not match
with the mass obtained for the compound in F2. Fractions F3, F5, F6 and F7 corresponded to other
amphidinol-related minor compounds.
The full A. carterae crude extract (5.7 g) was then fractionated through reverse phase C18 flash
chromatography. The compound detected in F2 (1.4 mg, accurate mass 1644.9437), now named
amphidinol 22, was isolated together with AM18 from the flash fractions 19 and 20 by semipreparative
reversed-phase HPLC.
3.2. Structure Identification
Amphidinol 22 was isolated as a pale yellow, amorphous solid. The data obtained from
HPLC-UV-MS analysis confirmed UV absorption maxima at 260, 270 and 280 nm, corresponding to the
presence of a conjugated triene in the structure, typical among the amphidinols. The molecular formula
of amphidinol 22 was deduced from the observed ammonium adduct [M + NH4]+ (m/z 1662.9705,
calculated m/z 1662.9717), indicative of a molecular formula C84H140O31 (degrees of unsaturation = 15).
Its 13C NMR spectrum revealed the presence of 79 different carbon signals (anticipating the
overlapping of some signals) of which 20 signals corresponded to sp2 carbons, covering 10 out of
the 15 unsaturations predicted by the molecular formula and suggesting the presence of five cycles.
A total of 33 carbon signals corresponded to oxygenated carbons in a region between δ55.11 and
δ82.36 ppm. Two of them presented a particularly shielded chemical shift (δC of 55.11 and 62.35),
typical in epoxide groups. The 1H NMR spectrum showed a high degree of signal overlap, especially
in the region of the oxygenated protons (δH from 3 to 4 ppm), hence the multiplicity of only a few
signals in the outermost regions was easily determined. The previous information together with the
2D-NMR hetero/homo-nuclear experiments performed (HSQC, COSY, HMBC and NOESY), allowed
the identification of the planar structure of amphidinol 22 (Figure 2) by linking spin systems and giving
information to overcome problems related to overlapped signals.
Mar. Drugs 2019, 17, x 7 of 13 
 
3.2. Structure Identification 
Amphidinol 2 was is l ted as a pale yellow, amorphous solid. The data obtained from HPLC-
UV-MS analysis confirmed UV absorption maxima at 260, 270 and 280 nm, corresponding to the 
presence of a conjugated triene in the structure, typical among the amphidinols. The molecular 
formula of amphidinol 22 was deduced from the observed ammonium adduct [M + NH4]+ (m/z 
1662.9705, calculated m/z 1662.9717), indicative of a molecular formula C84H140O31 (degrees of 
unsaturation = 15). 
Its 13C NMR spectrum revealed the presence of 79 different carbon signals (anticipating the 
overlapping of some signals) of which 20 signals corresponded to sp2 carbons, covering 10 out of the 
15 unsaturations predicted by the molecular formula and suggesting the presence of five cycles. A 
total of 33 carbon signals corresponded to oxygenated carbons in a region between δ55.11 and δ82.36 
ppm. Two of them presented a particularly shielded chemical shift (δC of 55.11 and 62.35), typical in 
epoxide groups. The 1H NMR spectrum showed a high degree of signal overlap, especially in the 
region of the oxygenated protons (δH from 3 to 4 ppm), hence the multiplicity of only a few signals in 
the outermost regions was easily determined. The previous information together with the 2D-NMR 
hetero/homo-nuclear experiments performed (HSQC, COSY, HMBC and NOESY), allowed the 
identification of the planar structure of amphidinol 22 (Figure 2) by linking spin systems and giving 
information t  overcome problems related to overlap  i l . 
 
Figure 2. Planar structure of amphidinol 22. 
The HSQC spectrum revealed that the carbon signals at δC 30.41 (2 CH2) and 33.59 (CH and CH2), 
and δ 36.68 (2CH2), 74.63 (2 CH) and 76.77 (2 CH) each accounted for two carbons, confirming the 
presence of 84 carbons in the molecule, and also confirmed that δ 136.85, δ 139.30, δ 144.65 and δ 
151.35 were signals corresponding to four sp2 quaternary carbons. A comparative approach with the 
data available from AM18 and AM19 [17], together with the COSY data from our molecule and the 
HMBC correlations when the overlapping in the 1H NMR signals was found (Table S9, 
Supplementary information), were used to establish the presence of four spin systems in the 
proposed structure (Figure 3): A (from H1 to H33), B (from H37 to H46), C (from H48 to H58) and, 
finally, D (from H60 to H78). Almost all COSY signals within the spin systems were well visible and, 
in addition, long distance COSY correlations were observed between H35, H80 and H81, confirming 
their proximity. The similarities of the chemical shifts with AM18 and the HMBC correlations 
confirmed the basic structure. 
Key HMBC correlations (Figure 3) allowed to link all the spin systems present in the structure. 
The cross-peaks at δ 2.29/18.51 (H33/C80), δ 2.29/129.54 (H33/C35), δ 2.29/136.85 (H33/C34), δ 
1.84/46.06 (H80/C33), δ 1.84/136.85 (H80/C34) and δ 1.84/129.54 (H80/C35), together with the signals 
at δ 2.27–2.21/115.77 (H37/C81), δ 2.27–2.21/144.65 (H37/C36), δ 2.27–2.21/129.54 (H37/C35), δ 5.05–
4.85/129.54 (H81/C35), δ 5.05–4.85/144.65 (H81/C36) and δ 5.05–4.85/47.72 (H81/C37), allowed to link 
the spin systems A and B. The HMBC signals H80/C35 and H81/C35, and previously reported COSY 
signals confirmed the position of CH-35. 
Spin system B and C were linked by the CH2-46 cross-peaks in the HMBC at δ 2.20–2.11/126.24 
(H46/C48), δ 2.20–2.11/139.30 (H46/C47) and δ 2.20–2.11/17.39 (H46/C83), in addition to those of the 
Figure 2. Planar structure of a phidinol 22.
The HSQC spectrum revealed that the carbon signals at δC 30.41 (2 CH2) and 33.59 (CH and
CH2), and δ 36.68 (2CH2), 74.63 (2 CH) and 76.77 (2 CH) each accounted for two carbons, confirming
the presence of 84 carbons in the molecule, and als confirmed that δ 136.85, δ 139.30, δ 144.65 and
δ 151.35 er rresponding to four sp2 quaternary carbons. A comparative approach with
the d t av ilable from AM18 and AM19 [17], together with the COSY data from our molecule
and the HMBC correlations w en the overlapping in the 1H NMR signals was found (Table S9,
Supplementary information), were used to establish the presenc of four spin system in the proposed
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structure (Figure 3): A (from H1 to H33), B (from H37 to H46), C (from H48 to H58) and, finally,
D (from H60 to H78). Almost all COSY signals within the spin systems were well visible and,
in addition, long distance COSY correlations were observed between H35, H80 and H81, confirming
their proximity. The similarities of the chemical shifts with AM18 and the HMBC correlations confirmed
the basic structure.
Key HMBC correlations (Figure 3) allowed to link all the spin systems present in the structure.
The cross-peaks at δ 2.29/18.51 (H33/C80), δ 2.29/129.54 (H33/C35), δ 2.29/136.85 (H33/C34), δ
1.84/46.06 (H80/C33), δ 1.84/136.85 (H80/C34) and δ 1.84/129.54 (H80/C35), together with the
signals at δ 2.27–2.21/115.77 (H37/C81), δ 2.27–2.21/144.65 (H37/C36), δ 2.27–2.21/129.54 (H37/C35), δ
5.05–4.85/129.54 (H81/C35), δ 5.05–4.85/144.65 (H81/C36) and δ 5.05–4.85/47.72 (H81/C37), allowed to
link the spin systems A and B. The HMBC signals H80/C35 and H81/C35, and previously reported
COSY signals confirmed the position of CH-35.
Spin system B and C were linked by the CH2-46 cross-peaks in the HMBC at δ 2.20–2.11/126.24
(H46/C48), δ 2.20–2.11/139.30 (H46/C47) and δ 2.20–2.11/17.39 (H46/C83), in addition to those of the
CH-48 signals at δ 5.48/17.39 (H48/C83) and δ 5.48/36.68 (H48/C46). This link was confirmed with
the HMBC correlations of the CH3-83 signals at δ 1.74/36.68 (H83/C46), δ 1.74/139.30 (H83/C47) and δ
1.74/126.24 (H83/C48).
Spin systems C and D were linked by the HMBC signals of CH2-58 at δ 2.41–2.09/151.35 (H58/C59),
δ 2.41–2.09/76.77 (H58/C60) and δ 2.41-2.09/113.21 (H58/C84), together with the CH-60 HMBC signals
at δ 4.18/151.35 (H60/C59), δ 4.18/27.89 (H60/C58) and δ 4.18/113.21 (H60/C84). This link was confirmed
with the cross-peaks displayed by CH2-84 signals at δ 5.07–4.98/27.89 (H84/C58), δ 5.07–4.98/151.35
(H84/C59) and δ 5.07–4.98/76.77 (H84/C60).
Finally, HMBC correlations also allowed to localize four ether bridges along the structure by the
through-oxygen cross-peaks at δ 3.14/81.54 (H20/C16), δ 4.22/74.63 (H23/C27), δ 3.48/79.21 (H55/C51)
and δ 3.74/70.41 (H66/C62).
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Figure 3. Spin systems and key HMBC correlations of amphidinol 22. The spin systems appear in
different colors as follows: A (black), B (blue), C (orange) and D (green).
The magnitude of the coupling constants of the signals belonging to the ∆4, ∆6, ∆69, ∆73 and ∆75
double bonds, higher than 15 Hz in all cases (see Table 1), allowed us to establish their E configuration.
NOESY signals observed for the pairs H33/H35 and H46/H48 also confirmed the E configuration of the
∆34 and ∆47 double bonds. Although determination of the full the three dimensional structure of the
molecule is out of the scope of this report, the configuration of the common substructure in amphidinol
22 might be the same as the one already reported for AM18, AM19, AM20 and AM21 (Figure 4), due to
similar chemical shifts and coupling constants around this region [17,21].
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3.3. Amphidinol 22 Bioactivities
In this section, the anticancer and antimicrobial bioactivities of amphidinol 22 are reported.
The compound was evaluated against five different cancer cell lines (i.e., A549, A2058, HepG2,
MCF7 and MiaPaca2) and five different microorganisms (i.e., A. fumigatus, C. albicans, MRSA, MSSA
and M. tuberculosis).
3.3.1. Anticancer Activity
MTT assays were performed on human lung carcinoma A549 ATCC® CCL-185™, human skin
melanoma A2058 ATCC® CRL-11147™, hepatocyte carcinoma HepG2 ATCC® HB-8065™, breast
adenocarcinoma MCF7 ATCC® HTB-22™ and pancreas carcinoma MiaPaca-2 ATCC® CRL-1420™ cell
lines to assay the potential anticancer activity of amphidinol 22. The compound displayed general
cytotoxicity on all the cell lines tested (Figure 5). Its IC50 values on A549, A2058, HepG2, MCF7 and
MiaPaca-2 cell lines were 8 µM, 16.4 µM, 6.8 µM, 16.8 µM and 8.6 µM, respectively.
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Figure 5. Percentage cell viability inhibition of A549 (lung), A2058 (skin), HepG2 (liver), MCF7 (breast)
and Miapaca-2 (pancreas) cancer cell lines after incubation for 72 h with 0.098, 0.195, 0.391, 0.781, 1.563,
3.125, 6.250, 12.5, 25, 50 µM of amphidinol 22 (** for p < 0.01 and *** for p < 0.001, Student’s t-test).
Experiments were performed in triplicate.
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The anticancer properties of another member of the amphidinol family, amphidinol 2 (AM2, first
isolated by Paul et al. [39]) were already reported by Espiritu et al. [29]. The anticancer activity was
evaluated against HCT-116 (colon carcinoma), HT29 (colon adenocarcinoma) and MCF-7 cancer cell
lines and IC50 values were in the range of 1 to 7 µM. An up-regulation (100-folds) of the early apoptotic
markers cfos/cjun, in all the cancer cells, was observed after treatment with AM2.
Other compounds from Amphidinium spp. have also been reported earlier to display anticancer
activity, such as the cytotoxic macrolides amphinolide G and amphinolide H. These two compounds,
especially amphidinolide H, exhibited extremely strong cytotoxic activities against L1210 murine
leukemia cells with IC50 values of 0.0054 and 0.00048 µg/mL and KB human epidermoid carcinoma
cells IC50 values of 0.0059 and 0.00052 µg/mL, respectively [40]. The mechanism of action was related
to covalent binding on the actin Tyr200 subdomain [41].
3.3.2. Antifungal Activity
The antifungal activity was assessed by testing amphidinol 22 against C. albicans and A. fumigatus
strains. The compound showed antifungal activity against both fungi, with a MIC value of 64 µg/mL
in both cases. Since isolation and identification of the first member of amphidinols’ family [27], almost
all the amphidinols discovered to date have presented antifungal activity. Echigoya and co-workers
showed a strong antifungal activity on Aspergillus niger for AM2, AM4 and AM9 (44.3, 58.2 and 32.9 µg
extract per disk, respectively) and a lower activity for AM10, AM11, AM12, AM13 (>100–256.6 µg
extract per disk) [20]. In addition, Nuzzo et al. showed that amphidinol 18 (AM18) was active
against the fungus C. albicans (9 µg/mL) [17]. In 2017, Satake et al. identified the largest amphidinol
homologues (AM20 and AM21) [21], but their antifungal activities were low compared to the activities
reported for AM6 and AM2 [22].
3.3.3. Antibacterial Activity
The anti-bacterial activity of amphidinol 22 was evaluated as well. Assays were performed on
Gram-positive bacteria (S. aureus MRSA and S. aureus MSSA) and M. tuberculosis, and no growth
inhibition was observed. Hence, the compound did not display any antibacterial effect.
4. Conclusions
Bioassay-guided fractionation allowed the isolation and identification of a new compound
belonging to the amphidinol family, which we designated as amphidinol 22, from the dinoflagellate
A. carterae. It presents different structural features when compared to the other related compounds,
including an extra pyran ring and an oxirane group. Bioactivity testing performed for this compound
showed that it has cytotoxic and antifungal properties. Amphidinol 22 cytotoxic activity was in range
with the already reported activities by Espiritu et al. for AM2 (1 to 7 µM) [29]. On the other hand,
AM18 and amphidinol A are the only amphidinols that have been tested for antifungal activity using
the MIC assay, and therefore the only studies we can use as a reference. However, the antifungal
activity of amphidinol 22 on C. albicans (MIC 64 µg/mL) is less potent compared to these molecules
(MIC 9 µg/mL for AM18 and 19 µg/mL for amphidinol A) [17,28].
In order to better characterize its mechanism of action, higher amounts of the compound are
necessary, as well as further research on biomedical, toxicological, chemical, pharmacological and
therapeutic potential. Microalgae have been shown to produce compounds with anticancer and
anti-microbial activities and to be cultivable for mass cultivation and massive compound production
in photobioreactors [1,12,42–47]. Until now, very few pure compounds have been isolated and
characterized from microalgae, and they are a still poorly explored resource for drug discovery.
This study confirm that they are an excellent reservoir of new marine natural products with applications
for various human pathologies.
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